Breaking News

Financial Report: Elan 3Q

October 25, 2012

Early stage business restructuring impacts earnings


3Q Revenues: $306.6 million (+10%)

3Q Loss: $13.7 million (earnings were $670.6 million in 3Q11)*

YTD Revenues: $883.0 million (+11%)

YTD Loss: $30.2 million  (earnings were $755.2 million YTD11)

Comments: Tysabri global in-market sales grew 3% to $403.8 million, reflecting a 17% growth in U.S. sales of Tysabri, offset by an 11% decrease in the rest of world. Loss in the quarter includes charges of $111.3 million related to the separation of the Neotope business and the discontinuation of Elan’s remaining early stage research activities, and an impairment charge of $117.3 million related to the Janssen AI equity method investment following J&J’s discontinuation of bapineuzumab intravenous in Alzheimer’s disease.

*Includes a gain of $664.0 million for the divestment of EDT business.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks